主要先進国におけるC型肝炎治療薬市場（～2019）...市場調査レポートについてご紹介

1 Table of Contents
1 Table of Contents 5
1.1 List of Tables 8
1.2 List of Figures 9
2 Introduction 10
2.1 Signs and Symptoms 10
2.2 Etiology and Risk Factors 11
2.3 Pathophysiology 11
2.4 Epidemiology 12
2.4.1 US and Canada 12
2.4.2 Europe 12
2.4.3 Japan 13
2.4.4 Regional Prevalence of Hepatitis C Genotypes 13
2.5 Prognosis 14
2.6 Diagnosis and Screening 16
2.7 Treatment 16
2.8 Treatment Algorithms 17
3 Marketed Products 21
3.1 Ribavirin 21
3.2 Pegasys (Peginterferon alfa 2a) and PegIntron (Peginterferon alfa 2b) – Hoffmann La Roche and Merck & Co 22
3.2.1 Pegasys – Hoffmann La Roche 24
3.2.2 PegIntron – Merck & Co 24
3.3 Incivek (telaprevir) – Vertex Pharmaceuticals and Janssen-Cilag 25
3.4 Victrelis (boceprevir) – Merck & Co 26
3.5 Olysio (simeprevir) – Johnson and Johnson 27
3.6 Sovaldi (sofosbuvir) – Gilead Sciences 28
3.7 Heat Map for Marketed Products 29
4 Developmental Pipeline 31
4.1 Overall Pipeline 31
4.2 Mechanisms of Action 33
4.3 Clinical Trials 35
4.3.1 Clinical Trial Failure Rates 36
4.3.2 Clinical Trial Enrollment 37
4.3.3 Clinical Trial Duration 39
4.3.4 Clinical Trial Design 41
4.4 Promising Pipeline Drugs 44
4.4.1 Sovaldi plus Ledipasvir – Gilead Sciences 44
4.4.2 Daclatasvir – Bristol-Myers Squibb 46
4.4.3 Faldaprevir – Boehringer-Ingelheim 49
4.4.4 Peginterferon lambda 1a – Bristol-Myers Squibb 50
4.4.5 ABT-450 – AbbVie and Enanta 52
4.4.6 Vaniprevir – Merck & Co 54
4.5 Heat Map and Competitor Matrix for Pipeline Products 55
4.6 Conclusion 59
5 Market Forecast to 2019 61
5.1 Global Market 62
5.1.1 Treatment Usage Patterns 62
5.1.2 Market Size 63
5.2 US 65
5.2.1 Treatment Usage Patterns 65
5.2.2 Market Size 66
5.3 Canada 67
5.3.1 Treatment Usage Patterns 67
5.3.2 Market Size 68
5.4 Top Five European Markets 69
5.4.1 Treatment Usage Patterns 69
5.4.2 Annual Cost of Therapy 72
5.4.3 Market Size 74
5.5 Japan 76
5.5.1 Treatment Usage Patterns 76
5.5.2 Market Size 77
6 Drivers and Barriers 78
6.1 Drivers 78
6.1.1 Approval of Sovaldi and Olysio in 2013 78
6.1.2 Large and Exceptionally Promising Late-Stage Pipeline 78
6.1.3 Favorable Pricing Structure in the US 78
6.1.4 Weak Exposure to Generics and Biosimilars during the Forecast Period 79
6.1.5 Increasing Volume of Treated Patients 79
6.1.6 Rapid Incorporation of Novel Products into Treatment Guidelines 79
6.2 Barriers 80
6.2.1 Low Rates of Diagnosis and Treatment in Certain Markets 80
6.2.2 Unfavorable Pricing Structures in the EU and Japan 80
6.2.3 Rapidly Increasing Competition in the Market 80
7 Licensing and Co-development deals 82
7.1 Licensing Deals 82
7.1.1 Vertex Pharma Enters into Licensing Agreement with Alios BioPharma for ALS-2200 and ALS-2158 85
7.1.2 Bristol-Myers Squibb Company Enters into Licensing Agreement with ZymoGenetics 85
7.1.3 Human Genome Sciences Enters Into Licensing Agreement With Novartis 85
7.1.4 Roche Signs Licensing Agreement With InterMune 85
7.1.5 Idenix Enters Into A Licensing Agreement With Novartis Pharma 86
7.1.6 Enanta Pharma Enters into Licensing Agreement with Novartis for Hepatitis C Program 86
7.1.7 Medivir Enters into Licensing Agreement with Tibotec 86
7.1.8 Metabasis Therapeutics Enters Into Collaboration And Licensing Agreement With Roche 86
7.1.9 Schering-Plough And PTC Therapeutics Enter Into A Collaboration And Licensing Agreement 87
7.1.10 Presidio Pharma Enters into Licensing Agreement with XTL BioPharma 87
7.2 Co-development Deals 88
7.2.1 Vertex Pharma Enters into Co-Development Agreement with Janssen Pharmaceutica 89
7.2.2 Abbott Labs Enters into Agreement with Enanta Pharma 89
7.2.3 Genelabs Enters into Collaboration with Novartis 89
7.2.4 Regulus Therapeutics Enters into an Agreement with GlaxoSmithKline 90
7.2.5 Tacere Therapeutics Enters into Agreement with Pfizer 90
7.2.6 Biota Holdings Enters into an Agreement with Boehringer Ingelheim 90
8 Appendix 91
8.1 Sources 91
8.2 Sources for Heat Maps 98
8.3 All Pipeline Products, by Stage of Development 99
8.3.1 Discovery 99
8.3.2 Preclinical and IND/CTA-filed 102
8.3.3 Phase I 106
8.3.4 Phase II 107
8.3.5 Phase III and Pre-registration 110
8.3.6 Undisclosed 111
8.4 Tabular Forecast Data 112
8.4.1 Global 112
8.4.2 US 113
8.4.3 Canada 113
8.4.4 UK 113
8.4.5 France 114
8.4.6 Germany 114
8.4.7 Italy 114
8.4.8 Spain 115
8.4.9 Japan 115
8.5 Market Definition 115
8.6 Abbreviations 115
8.7 Methodology 116
8.7.1 Coverage 116
8.7.2 Secondary Research 117
8.7.3 Primary Research 117
8.7.4 Therapeutic Landscape 117
8.7.5 Epidemiology-Based Forecasting 118
8.7.6 Market Size by Geography 119
8.7.7 Geographical Landscape 120
8.7.8 Pipeline Analysis 120
8.8 Contact Us 120
8.9 Disclaimer 120